336 related articles for article (PubMed ID: 31563982)
21. MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma.
Fujii K; Murase T; Beppu S; Saida K; Takino H; Masaki A; Ijichi K; Kusafuka K; Iida Y; Onitsuka T; Yatabe Y; Hanai N; Hasegawa Y; Inagaki H
Histopathology; 2017 Nov; 71(5):823-834. PubMed ID: 28594149
[TBL] [Abstract][Full Text] [Related]
22. Small Subset of Adenoid Cystic Carcinoma of the Skin Is Associated With Alterations of the MYBL1 Gene Similar to Their Extracutaneous Counterparts.
Kyrpychova L; Vanecek T; Grossmann P; Martinek P; Steiner P; Hadravsky L; Belousova IE; Shelekhova KV; Svajdler M; Dubinsky P; Michal M; Kazakov DV
Am J Dermatopathol; 2018 Oct; 40(10):721-726. PubMed ID: 29570128
[TBL] [Abstract][Full Text] [Related]
23. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma.
Brayer KJ; Frerich CA; Kang H; Ness SA
Cancer Discov; 2016 Feb; 6(2):176-87. PubMed ID: 26631070
[TBL] [Abstract][Full Text] [Related]
24. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
[TBL] [Abstract][Full Text] [Related]
25. MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas.
Tatevossian RG; Tang B; Dalton J; Forshew T; Lawson AR; Ma J; Neale G; Shurtleff SA; Bailey S; Gajjar A; Baker SJ; Sheer D; Ellison DW
Acta Neuropathol; 2010 Dec; 120(6):731-43. PubMed ID: 21046410
[TBL] [Abstract][Full Text] [Related]
26. Leat-associated seizures the possible role of EAAT2, pyruvate carboxylase and glutamine synthetase.
Buccoliero AM; Caporalini C; Moscardi S; Cetica V; Mei D; Conti V; Nozzoli F; Bonaudo C; Battista F; Giordano F; Mura R; Spacca B; Mussa F; D'Onofrio V; Guerrini R; Genitori L; Scagnet M
Epilepsy Res; 2024 Jan; 199():107258. PubMed ID: 38086219
[TBL] [Abstract][Full Text] [Related]
27. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of MYB/MYBL1-altered pediatric-type diffuse low-grade glioma.
Moreira DC; Qaddoumi I; Spiller S; Bouldin TW; Davidson A; Saba-Silva N; Sullivan DV; Tanaka R; Wagner AS; Wood M; Klimo P; Job G; Devidas M; Li X; Gajjar A; Robinson GW; Chiang J
Neuro Oncol; 2024 Mar; ():. PubMed ID: 38466086
[TBL] [Abstract][Full Text] [Related]
29. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
[TBL] [Abstract][Full Text] [Related]
30. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
[TBL] [Abstract][Full Text] [Related]
31. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
32. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
Ammendola S; Broggi G; Barresi V
Histol Histopathol; 2023 Jul; 38(7):739-753. PubMed ID: 36651583
[TBL] [Abstract][Full Text] [Related]
33. An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update.
Lassaletta A; Zapotocky M; Bouffet E; Hawkins C; Tabori U
Childs Nerv Syst; 2016 Oct; 32(10):1789-97. PubMed ID: 27659822
[TBL] [Abstract][Full Text] [Related]
34. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
35. 2021 updates to the World Health Organization classification of adult-type and pediatric-type diffuse gliomas: a clinical practice review.
Thomas DL
Chin Clin Oncol; 2023 Feb; 12(1):7. PubMed ID: 36922356
[TBL] [Abstract][Full Text] [Related]
36. A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment.
Ryall S; Tabori U; Hawkins C
Brain Tumor Pathol; 2017 Apr; 34(2):51-61. PubMed ID: 28342104
[TBL] [Abstract][Full Text] [Related]
37. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
[TBL] [Abstract][Full Text] [Related]
38. Molecular and clinicopathologic features of gliomas harboring NTRK fusions.
Torre M; Vasudevaraja V; Serrano J; DeLorenzo M; Malinowski S; Blandin AF; Pages M; Ligon AH; Dong F; Meredith DM; Nasrallah MP; Horbinski C; Dahiya S; Ligon KL; Santi M; Ramkissoon SH; Filbin MG; Snuderl M; Alexandrescu S
Acta Neuropathol Commun; 2020 Jul; 8(1):107. PubMed ID: 32665022
[TBL] [Abstract][Full Text] [Related]
39. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.
Granberg KJ; Annala M; Lehtinen B; Kesseli J; Haapasalo J; Ruusuvuori P; Yli-Harja O; Visakorpi T; Haapasalo H; Nykter M; Zhang W
Neuro Oncol; 2017 Sep; 19(9):1206-1216. PubMed ID: 28379477
[TBL] [Abstract][Full Text] [Related]
40. The genomic landscape of dysembryoplastic neuroepithelial tumours and a comprehensive analysis of recurrent cases.
Pagès M; Debily MA; Fina F; Jones DTW; Saffroy R; Castel D; Blauwblomme T; Métais A; Bourgeois M; Lechapt-Zalcman E; Tauziède-Espariat A; Andreiuolo F; Chrétien F; Grill J; Boddaert N; Figarella-Branger D; Beroukhim R; Varlet P
Neuropathol Appl Neurobiol; 2022 Oct; 48(6):e12834. PubMed ID: 35836307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
